Ausgabe 6/2011
Inhalt (32 Artikel)
Translational research of a novel humanized epidermal growth factor receptor-related protein: a putative inhibitor of pan-ErbB
Xian-Hua Fu, Jun Li, Jian-Jin Huang, Shu Zheng, Su-Zhan Zhang
Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors
Patricia LoRusso, Geoffrey I. Shapiro, Herbert Hurwitz, Mary Jo Pilat, Janice Chemidlin, Georgia Kollia, Shariq Syed, Bruce Fischer, Eric Masson
t(11;18)(q21;q21) translocation as predictive marker for non-responsiveness to salvage thalidomide therapy in patients with marginal zone B-cell lymphoma with gastric involvement
Sung-Hsin Kuo, Ann-Lii Cheng, Chung-Wu Lin, Chih-Hung Hsu, Ming-Shiang Wu, Kun-Huei Yeh, Yi-Shin Tzeng, Li-Tzong Chen
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies
P. Schöffski, H. Dumez, R. Ruijter, B. Miguel-Lillo, A. Soto-Matos, V. Alfaro, G. Giaccone
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation
Giulio Metro, R. Chiari, M. Mare, D. Giannarelli, F. R. Tofanetti, V. Minotti, M. Ferraldeschi, D. Giuffrida, L. Marcomigni, C. Bennati, M. J. Fischer, M. Meacci, R. Bellavita, L. Pistola, V. Ludovini, L. Crinò
Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer
N. Frances, L. Claret, R. Bruno, A. Iliadis
Dihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway
Shuang-Jia Wang, Bei Sun, Zhuo-Xin Cheng, Hao-Xin Zhou, Yue Gao, Rui Kong, Hua Chen, Hong-Chi Jiang, Shang-Ha Pan, Dong-Bo Xue, Xue-Wei Bai
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
David Fogelman, Mehrdad Jafari, Gauri R. Varadhachary, Henry Xiong, Susie Bullock, Harold Ozer, E. Lin, Jeffrey Morris, Patti Cunningham, Bronwyn Bennett, James L. Abbruzzese, Robert A. Wolff
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study
Ticiana B. Leal, Scot C. Remick, Chris H. Takimoto, Ramesh K. Ramanathan, Angela Davies, Merrill J. Egorin, Anne Hamilton, Patricia A. LoRusso, Stephen Shibata, Heinz-Josef Lenz, James Mier, John Sarantopoulos, Sridhar Mani, John J. Wright, S. Percy Ivy, Rachel Neuwirth, Lisa von Moltke, Karthik Venkatakrishnan, Daniel Mulkerin
Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation
Cristina P. R. Xavier, Cristovao F. Lima, Mikkel Rohde, Cristina Pereira-Wilson
Resveratrol induces SIRT1- and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment
My Björklund, Jeanette Roos, Vladimir Gogvadze, Maria Shoshan
Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma
Robin E. Norris, Jane E. Minturn, Garrett M. Brodeur, John M. Maris, Peter C. Adamson
Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study
Peter Mu-Hsin Chang, Cheng-Hwai Tzeng, Ming-Huang Chen, Chao-Jung Tsao, Wu-Chou Su, Wei-Shuo Hwang, Yi-Fang Chang, Shyue-Yih Chang, Muh-Hwa Yang
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib
Jiri Horak, Jeff White, Adrian L. Harris, Mark Verrill, James Carmichael, Alison Holt, Mireille Cantarini, Merran Macpherson, Alan Swaisland, Helen Swaisland, Chris Twelves
Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer
Fatma Sen, Esra Kaytan Saglam, Alper Toker, Sukru Dilege, Ahmet Kizir, Ethem Nezih Oral, Pinar Saip, Barkin Sakallioglu, Erkan Topuz, Adnan Aydiner
Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer
Apostolia-Maria Tsimberidou, Nancy Lewis, Tony Reid, Howard Burris, Patrick Urban, Eugene Y. Tan, Suraj Anand, Cynthia Uehara, Razelle Kurzrock
Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor
Elena Soto, Alexander Staab, Christiane Doege, Matthias Freiwald, Gerd Munzert, Iñaki F. Trocóniz
Pharmacokinetic evaluation of the vinorelbine–lapatinib combination in the treatment of breast cancer patients
Keyvan Rezai, S. Urien, N. Isambert, H. Roche, V. Dieras, J. Berille, J. Bonneterre, E. Brain, F. Lokiec
Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells
Rebecca G. Bagley, Leslie Kurtzberg, Cecile Rouleau, Min Yao, Beverly A. Teicher
Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model
Cecilia Engmér Berglin, Pernilla Videhult Pierre, Tobias Bramer, Katarina Edsman, Hans Ehrsson, Staffan Eksborg, Göran Laurell
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
Ario Takeuchi, Masaki Shiota, Katsunori Tatsugami, Akira Yokomizo, Masatoshi Eto, Junichi Inokuchi, Kentaro Kuroiwa, Keijiro Kiyoshima, Seiji Naito
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
Muhammad Wasif Saif, John Sarantopoulos, Amita Patnaik, Anthony W. Tolcher, Chris Takimoto, Murali Beeram
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials
Daniel Binder, Ralf-Harto Hübner, Bettina Temmesfeld-Wollbrück, Peter Schlattmann
Preclinical evaluation of the novel multi-targeted agent R1530
Kenneth Kolinsky, Christian Tovar, Yu-E Zhang, Aruna Railkar, Hong Yang, Daisy Carvajal, Thomas Nevins, Wanping Geng, Michael Linn, Kathryn Packman, Jin-Jun Liu, Zhuming Zhang, Peter Wovkulich, Grace Ju, Brian Higgins
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202
Syma Iqbal, Cathryn Rankin, Heinz-Josef Lenz, Philip J. Gold, Syed A. Ahmad, Anthony B. El-Khoueiry, Michael J. Messino, Randall F. Holcombe, Charles D. Blanke
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy
Tomomi Egawa-Takata, Yutaka Ueda, Chie Kuragaki, Takahito Miyake, Takashi Miyatake, Masami Fujita, Kiyoshi Yoshino, Ryuichi Nakashima, Mika Okazawa, Tateki Tsutsui, Ken-Ichirou Morishige, Tadashi Kimura, Masato Yamasaki, Takamichi Nishizaki, Masaaki Nagamatsu, Kimihiko Ito, Masahiro Asada, Kazuhide Ogita, Akinori Wakimoto, Toshiya Yamamoto, Yukihiro Nishio, Takayuki Enomoto
Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency
Maurice C. van Staveren, Barbara Theeuwes-Oonk, Henk Jan Guchelaar, André B. P. van Kuilenburg, Jan Gerard Maring
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Suzanne Leijen, Patricia M. M. B. Soetekouw, T. R. Jeffry Evans, Marianne Nicolson, Jan H. M. Schellens, Maria Learoyd, Lynda Grinsted, Victoria Zazulina, Thinn Pwint, Mark Middleton
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
Jacqueline Ramírez, Kehua Wu, Linda Janisch, Theodore Karrison, Larry K. House, Federico Innocenti, Ezra E. W. Cohen, Mark J. Ratain
Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity
Romain Guilhaumou, Caroline Solas, Veronique Bourgarel-Rey, Sylvie Quaranta, Angelique Rome, Nicolas Simon, Bruno Lacarelle, Nicolas Andre
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Fabio Farinati, Anna Giacomin, Veronica Vanin
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function
Jeong Eun Kim, Baek-Yeol Ryoo, Yoon-Koo Kang